Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Inpatient, Placebo-Controlled Study of ALLN-346 (Engineered Urate Oxidase) in Hyperuricemic Subjects

NCT04987242 is registered in ClinicalTrials.gov with Allena Pharmaceuticals as lead sponsor.

NCT NCT04987242
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04987242 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Inpatient, Placebo-Controlled Study of ALLN-346 (Engineered Urate Oxidase) in Hyperuricemic Subjects
Lead sponsor
Allena Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
July 16, 2021
Completion date
March 2, 2022
Enrollment
16 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney diseases, gout, hyperuricemia